Accueil / Communiqués / H.I.G. Capital Completes Acquisition of Taconic Biosciences

H.I.G. Capital Completes Acquisition of Taconic Biosciences

Thursday, February 7th 2019 at 1:00pm UTC

BOSTON–(BUSINESS WIRE)– H.I.G. Capital (« H.I.G. »), a leading global private equity investment
firm with $30 billion of equity capital under management*, is pleased to
announce that one of its affiliates has partnered with the management
team of Taconic Biosciences, Inc., (“Taconic” or the “Company”) to
support the Company’s growth as a leading global provider of research
models and services to the pharmaceutical, biotechnology, CRO, and
academic research industries.

Headquartered in Rensselaer, NY, with operations in Germantown, NY,
Indiana, Germany, and Denmark, Taconic is a global leader in genetically
engineered models and service solutions used in mission-critical life
sciences research. With its strong market position and long-standing
relationships, Taconic is well-positioned to benefit from the
significant growth in the broader healthcare services market and more
specifically in genetically engineered models growth. Researchers use
Taconic’s models and services in a wide variety of growing research
applications, including oncology, immunology, and neuroscience, as well
as other established and emerging therapeutic areas.

“Taconic’s scientific expertise, customer-first mentality, outstanding
quality and service standards, and full suite of capabilities provide a
differentiated end-to-end solution that offers unique value to the
growing life sciences market,” said John Von Bargen, a Managing Director
at H.I.G. “We are excited to support Taconic’s exceptional leadership
team as they look to expand the Company’s geographic footprint,
partnership base, and product and service offerings.”

Former CEO Dr. Robert Rosenthal was named Chairman of Taconic’s Board of
Directors as well as the Company’s Chief Innovation Officer, helping
guide the Company’s strategic direction. Also joining the board is Alex
Zisson, a Managing Director of H.I.G. BioHealth Partners, the dedicated
life-science investment affiliate of H.I.G. Alex has spent over two
decades in the healthcare investment and research industries covering
biotechnology, specialty pharmaceuticals, drug delivery, and diagnostics
industries.

“Taconic Biosciences is at a very exciting point in its growth
trajectory. We are confident the partnership with H.I.G. positions us to
continue delivering world-class problem solving solutions to our
customers, while providing the resources required to achieve our
strategic plan,” said Dr. Robert Rosenthal. Nancy Sandy, Taconic’s new
Chief Executive Officer added, “H.I.G.’s investment and deep resources,
particularly around M&A, will help catalyze our continued expansion and
allow us to more quickly address unmet customer needs.”

About Taconic Biosciences

Taconic Biosciences is a fully-licensed, global leader in genetically
engineered models and services. Founded in 1952, Taconic provides the
best murine solutions so that customers can acquire, custom generate,
breed, precondition, test, and distribute valuable research models
worldwide. Specializing in genetically engineered models, precision
research models, and integrated model design and husbandry services,
Taconic operates three service laboratories and six husbandry facilities
in the U.S. and Europe, maintains distributor relationships in Asia and
has global shipping capabilities to provide models almost anywhere in
the world.

About H.I.G. Capital

H.I.G. is a leading global private equity and alternative assets
investment firm. Based in Miami, and with offices in New York, Boston,
Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as
well as international affiliate offices in London, Hamburg, Madrid,
Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes
in providing both debt and equity capital to small and mid-sized
companies, utilizing a flexible and operationally focused/ value-added
approach:

  1. H.I.G.’s equity funds invest in management buyouts, recapitalizations
    and corporate carve-outs of both profitable as well as underperforming
    manufacturing and service businesses.
  2. H.I.G.’s debt funds invest in senior, unitranche and junior debt
    financing to companies across the size spectrum, both on a primary
    (direct origination) basis, as well as in the secondary markets.
    H.I.G. is also a leading CLO manager, through its WhiteHorse family of
    vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. H.I.G.’s real estate funds invest in value-added properties, which can
    benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than
300 companies worldwide. The firm’s current portfolio includes more than
100 companies with combined sales in excess of $30 billion. www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and
affiliates.

Contacts

John Von Bargen
Managing Director
jvonbargen@higcapital.com
www.higcapital.com

Source: H.I.G. Capital


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …